These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 22902171)

  • 1. Neuroprevention: a new challenge?
    Corvol JC
    Rev Neurol (Paris); 2012 Nov; 168(11):796-801. PubMed ID: 22902171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of preclinical diagnosis and preventive treatment of neurodegenerative diseases].
    Ugrumov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(11):4-14. PubMed ID: 26978045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New concepts of pathogenesis, diagnosis, and treatment of neurodegenerative diseases].
    Ugriumov MV
    Vestn Ross Akad Med Nauk; 2010; (8):6-19. PubMed ID: 20919532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The presymptomatic phase of Huntington disease.
    Durr A; Gargiulo M; Feingold J
    Rev Neurol (Paris); 2012 Nov; 168(11):806-8. PubMed ID: 22902173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O
    Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical considerations of biomarker use in neurodegenerative diseases--a case study of Alzheimer's disease.
    Prvulovic D; Hampel H
    Prog Neurobiol; 2011 Dec; 95(4):517-9. PubMed ID: 22137044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
    Auxéméry Y
    Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological targets in neurodegenerative diseases].
    Segura T; Galindo MF; Rallo-Gutiérrez B; Ceña V; Jordán J
    Rev Neurol; 2003 Jun 1-15; 36(11):1047-57. PubMed ID: 12808502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family centred decision making and non-disclosure of diagnosis in a South East Asian oncology practice.
    Back MF; Huak CY
    Psychooncology; 2005 Dec; 14(12):1052-9. PubMed ID: 15834966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predementia Alzheimer's disease. Benefits of early diagnosis].
    Viloria A
    Rev Esp Geriatr Gerontol; 2011 Oct; 46 Suppl 1():47-54. PubMed ID: 22152916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When does Parkinson's disease begin? From prodromal disease to motor signs.
    Meissner WG
    Rev Neurol (Paris); 2012 Nov; 168(11):809-14. PubMed ID: 22981298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection by tetracyclines.
    Domercq M; Matute C
    Trends Pharmacol Sci; 2004 Dec; 25(12):609-12. PubMed ID: 15530637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.
    Lieberman JA; Malaspina D; Jarskog LF
    CNS Spectr; 2006 Apr; 11(4):suppl 1-13; quiz suppl 14-5. PubMed ID: 16641837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder.
    Ziemann U; Wahl M; Hattingen E; Tumani H
    Prog Neurobiol; 2011 Dec; 95(4):670-85. PubMed ID: 21524682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a relation between extremely low frequency magnetic field exposure, inflammation and neurodegenerative diseases? A review of in vivo and in vitro experimental evidence.
    Mattsson MO; Simkó M
    Toxicology; 2012 Nov; 301(1-3):1-12. PubMed ID: 22750629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurodegeneration in multiple sclerosis: novel treatment strategies.
    Luessi F; Siffrin V; Zipp F
    Expert Rev Neurother; 2012 Sep; 12(9):1061-76; quiz 1077. PubMed ID: 23039386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacotherapy for degenerative dementias].
    Maloteaux JM
    Bull Mem Acad R Med Belg; 2005; 160(1-2):109-17; discussion 118-22. PubMed ID: 16116815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Looking backward to move forward: early detection of neurodegenerative disorders.
    DeKosky ST; Marek K
    Science; 2003 Oct; 302(5646):830-4. PubMed ID: 14593169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Which properties are necessary for a marker in early and differential diagnosis of neurodegenerative disease?].
    Kornhuber J; Thürauf N; Lewczuk P
    Fortschr Neurol Psychiatr; 2010 Aug; 78(8):443-4. PubMed ID: 20694937
    [No Abstract]   [Full Text] [Related]  

  • 20. [Review on the neuroprotective effects of green tea polyphenols for the treatment of neurodegenerative diseases].
    Li Q; Li Y
    Wei Sheng Yan Jiu; 2010 Jan; 39(1):123-6. PubMed ID: 20364607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.